Search results

748 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
NICE Pathways Remove NICE Pathways filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter

Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]

In development [GID-TA10171] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Peramivir for treating influenza [ID828]

In development [GID-TA10155] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

In development [GID-TA10177] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

In development [GID-TA10159] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lenalidomide for untreated follicular lymphoma ID1245

In development [GID-TA10308] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

In development [GID-TA10353] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Constipation (opioid induced) - methylnaltrexone bromide [ID700]

In development [GID-TA10003] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (chronic lymphocytic) - idelalisib (with ofatumumab) [ID817]

In development [GID-TA10008] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

In development [GID-TA10236] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]

In development [GID-TA10028] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

In development [GID-MT516] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab ID1487

In development [GID-TA10437] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997

In development [GID-TA10382] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]

In development [GID-TA10338] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

In development [GID-TA10151] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable ID1492

In development [GID-TA10441] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

In development [GID-TA10154] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Renal cell carcinoma - sunitinib [ID1076]

In development [GID-TA10166] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Osteoarthritis - diacerein [ID332]

In development [GID-TAG250] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172

In development [GID-TA10394] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

In development [GID-TA10446] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for previously treated platinum-resistant ovarian cancer ID1497

In development [GID-TA10404] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

In development [GID-TA10024] Expected publication date: 28 June 2017

Type

Technology appraisal guidance

Status

In development
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

In development [GID-TA10046] Expected publication date: 22 November 2017

Type

Technology appraisal guidance

Status

In development
Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]

In development [GID-TAG431] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

In development [GID-TAG363] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

In development [GID-TAG425] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pulmonary arterial hypertension (adults) - drugs [ID12]

In development [GID-TAG382] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]

In development [GID-TAG444] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer - intensity modulated radiotherapy [ID16]

In development [GID-TAG390] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

In development [GID-TA10445] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

In development [GID-TA10337] Expected publication date: 19 February 2020

Type

Technology appraisal guidance

Status

In development
Pacritinib for treating myelofibrosis [ID880]

In development [GID-TA10133] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
OraQuick® HCV Rapid Antibody Test (discontinued)

In development [GID-MT117] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
LJ TEST

In development [GID-TA10462] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288

In development [GID-TA10212] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

In development [GID-TA10271] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

In development [GID-TA10575] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Sotagliflozin for treating type 2 diabetes [ID1657]

Proposed [GID-TA10665] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Spasticity (after stroke) - botulinum toxin type A [ID768]

In development [GID-TAG499] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

In development [GID-TA10105] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

In development [GID-TA10089] Expected publication date: 15 November 2017

Type

Technology appraisal guidance

Status

In development
Eculizumab for treating relapsing neuromyelitis optica [ID1271]

In development [GID-TA10469] Expected publication date: 02 September 2020

Type

Technology appraisal guidance

Status

In development
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179

In development [GID-TA10450] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]

In development [GID-TA10653] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

In development [GID-TA10635] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development